|Base Year Market Size
|USD 6.83 Billion
|Forecast Year Market Size
|USD 14.63 Billion
|Fastest Growing Market
The Global Hemostasis & Tissue Sealing Agents Market was valued at USD 6.83 billion in 2021 and is predicted to reach at USD 14.63 billion by 2030, increasing at a CAGR of 8.83% from 2022 to 2030.
Biological systems, such as hemostasis, keep blood flowing by preventing the loss of blood from the body. This condition is known as hemostasis because it is caused by the body's coagulation process being activated. Major surgeries and injuries necessitate blood loss that cannot be controlled by the body's natural healing process. As a result, hemostats and tissue-sealing agents can help in certain instances by reducing blood loss and aiding in the healing process. To prevent excessive bleeding during surgical procedures, hemostats and tissue sealing agents are becoming increasingly used.
In addition, severe bleeding can lead to postoperative issues such as longer surgical operations and a lack of blood in the body. For this reason, it is critical to avoid such incidents from occurring in order to ensure excellent patient outcomes and successful surgical outcomes. Thus, topical hemostats, such as mechanical hemostats, active hemostats, and Flowable hemostats, are applied directly on the bleeding site along with natural and synthetic tissue sealants in order to restrict blood loss.
Over the course of the last few years, there has been a discernible shift toward a preference for minimally invasive surgical procedures. A shorter hospital stays, a smaller incision, fewer difficulties after surgery, and a quicker recovery period are some of the benefits that come with undergoing minimally invasive surgery. In minimally invasive treatments, the use of systemic hemostatic drugs such gelatin and collagen-based hemostat powders is commonplace. Surgeons are able to undertake intricate procedures thanks to these substances. According to the findings of a study that was carried out by the World Health Organization (WHO), there are roughly 234.2 million major surgical procedures that are performed each year in hospitals and other surgical centers all over the world. As a result, an increase in the total number of surgical procedures as well as a growing preference for minimally invasive treatments leads to an increase in the demand for hemostats and tissue sealing agents.
The desire for surgical procedures that are less invasive has been driven in part by the growing number of elderly people around the world. This demand, in turn, is promoting the expansion of the market for hemostasis tissue sealing agents. The increasing popularity of minimally invasive operations can be attributed to the numerous benefits that come as a result of undergoing these kinds of surgical procedures. These advantages include a shorter amount of time spent in the hospital, a lower risk of post-operative problems, a shorter amount of time needed for recuperation, and fewer incisions. In these particular kinds of surgical operations, the products that are available on the global market for hemostasis tissue sealing agents, such as collagen and gelatin-based systemic hemostasis agents, are utilized the majority of the time. The need for hemostasis and tissue sealing agents in the global market is being driven by this factor.
The development of hemostats and tissue sealants is a process that is both complicated and expensive. The regulatory approval of hemostat products requires reliable scientific data, investigations that have been carefully monitored, and case studies that have been thoroughly documented. In spite of the significant financial investment that manufacturers make in the research and development of hemostat devices, the approval rate for these goods by regulatory authorities is dismally low. The low approval rate of hemostat products has been linked to a number of factors, including the products' poor efficacy and safety. Because of the challenges that hemostat producers have encountered in clinical studies, a relatively limited number of companies have joined the market. The expansion of the market for hemostasis and tissue sealing agents is hampered as a result of this.
It is anticipated that the topical hemostat market would maintain its position as the dominant one throughout the projected period. This market category was also the most important contributor to total growth in 2021. In order to effectively control bleeding during surgical procedures, topical hemostats are an absolute necessity. During these types of surgeries, the hemostats serve to lower the risk of post-operative problems. As a result of all of these factors, the topical hemostats sector will be able to increase during the forecast period, which will provide lucrative opportunities for the expansion of the Hemostasis and Tissue Sealing Agents market. In addition, the development of innovative technologies in the pharmaceutical and biotechnology industries are also contributing to the expansion of the Global Hemostasis Tissue Sealing Agents market during the past few years.
The Global Hemostasis & Tissue Sealing Agents Market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Due to the rising incidence of cancer, diabetes, and cardiovascular diseases there, North America held the greatest market share. A sizable portion of the North American market is made up of adhesives and sealants. Europe, which ranked second in terms of market size in 2021, is anticipated to grow at a CAGR of almost 8.2 percent during the forecast period. The introduction of cutting-edge and ground-breaking products like FLOSEAL, TISEEL, and HEMOPATCH is anticipated to boost demand from European nations. The increasing senior population, which ultimately results in a larger number of surgeries, is anticipated to drive the regional market.
The growing need for quicker and more effective healing after surgery is the main factor driving the market for hemostasis and tissue sealing agents in Italy. The market for hemostasis and tissue sealing agents in Italy is anticipated to develop even more as healthcare spending rises. Growing understanding of the use of hemostatic agents, adhesives, and tissue sealants to reduce the risk of postoperative bleeding is one of the key drivers of market expansion in Spain. Throughout order to promote education and awareness, numerous conferences are held in Spain.
The extensive marketing of such gadgets in the area is the main reason for the significant share. Other reasons promoting growth include the regular introduction of new products, expanding uses for such devices in operations and other medical procedures, as well as the desire for sealing agents that reduce post-operative problems and accelerate recovery.
Due to an increase in surgical operations and medical tourism, Asia Pacific is anticipated to have profitable growth during the forecast period. The main forces behind the region's growth are liberal policies combined with an environment that is economical. The top three nations with the most advanced medical technology, the largest patient populations, and the most developed healthcare infrastructure are India, China, and Japan. With a thriving medical tourism industry and better healthcare facilities thanks to government assistance, the market in Malaysia, Singapore, and other Asian nations is growing quickly.
Over the projected period, growth is anticipated in the Indian market for hemostasis and tissue sealing agents. Increased healthcare spending, the existence of less restrictive restrictions on the use of such medical devices, reduced costs, and an abundance of labor, which promote manufacturers' easy entry into this region, are the main drivers of market expansion.
|B Braun Medical, Inc. Baxter Advance Medical Solution (AMS) Group Plc Integra Life Sciences Corporation Johnson & Johnson Cohera Medical, Inc. Cohesion Technologies, Inc. MIL Laboratories Pvt., Ltd. Pfizer, Inc. Covidien Plc. Smith & Nephew CryoLife, Inc. HyperBranch Medical Technology. Biomet, Inc. C R Bard, Inc.
|U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
|China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
|Middle East and Africa
|UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
|Brazil Mexico Argentina Chile Colombia Rest of LATAM
|Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The Global Hemostasis & Tissue Sealing Agents Market is divided into different segments according to the Product and Region (Geography).
By Product, the Global Hemostasis & Tissue Sealing Agents Market is segmented into Topical Hemostat and Adhesives & Tissue Sealant. Topical hemostats and tissue sealants are two of the most important product areas that were investigated for this study. Hemostats that are applied to the skin can be further divided into three categories: mechanical, active, and flow-able. It is common practice to combine conventional treatment with the use of topical hemostats since this combination offers the benefits of cost-effectiveness, rapid and simple absorbability of the hemostatic agent, little tissue reaction, and non-antigenicity.
The completion of the coagulation, fibrinolysis, and platelet aggregation pathways is necessary for proper hemostasis, which is accomplished through the activation of these components. Hemostats are made up of hemostatic agents and their respective delivery systems. These delivery systems might be in the form of a prefilled syringe or ready-to-use applicators.
During surgical procedures, the use of adhesives and sealants is crucial to minimizing the amount of blood that is lost. They accomplish this by attaching to the injured tissues and then sealing them off. The act of binding results in the formation of a barrier over the injuries and surgical wound, which both helps promote coagulation and reduces the risk of infection. Their increased demand over sutures can be attributed to a number of causes, including a quicker procedure rate, little invasion, a reduction in post-surgical infections, and the prevention of other body fluids from exuding. These are further subdivided into synthetic, natural, and adhesion barrier products according to the sealants that are utilized in their production.
By Region, the Global Hemostasis & Tissue Sealing Agents Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Because of the rising incidence of heart disease, diabetes, and cancer in the region, North America commanded the greatest part of the market. The North American market is dominated by adhesives and sealants. In 2021, Europe will be the second-largest market, and it is predicted to grow at an annual rate of 8.2 percent.
The strong marketing of such gadgets in the region is a major contributor to the high market share. There is also a growing demand for sealing agents that reduce post-operative difficulties and speed up recovery, as well as the regular introduction of new products that all contribute to the expansion.
Increasing medical tourism and surgical operations in the region are predicted to fuel lucrative expansion in the Asia-Pacific region over the forecast period. The region's prosperity is fueled by liberal policies and a cost-effective environment. Healthcare systems in China, India, and Japan are substantially more modern, with a larger patient base and more advanced treatments.
June 2022 - Valneva SE, a speciality vaccine business, and Pfizer Inc. have revised their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As stated on April 26, 2022, Pfizer aims to start VLA15's Phase 3 research in the third quarter of 2022.
January 2022 - CryoLife, Inc., a premier cardiac and vascular surgical firm focused on aortic disease, is now Artivion, Inc. The company's new name and brand reflect its focus on providing revolutionary technologies to aortic surgeons. The company's ticker symbol on the New York Stock Exchange will change to "AORT" from "CRY" on January 24, 2022.